Revolutionizing bladder cancer research: Harnessing 3D organoid technology to decode tumor heterogeneity and propel personalized therapeutics
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025
DOI: 10.1016/j.bbcan.2025.189454 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Helin Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital& Institute, No.44 Xiaoheyan Road, Dadong District, S…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Organoids, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Liaoning Province, Natural Science Foundation of Liaoning Province.
Abstract (Originalsprache)
Bladder cancer (BC), characterized by remarkable tumor heterogeneity, remains a challenging malignancy with limited therapeutic options. Emerging three-dimensional (3D) organoid models are transforming our understanding of BC biology by closely mimicking the complex tumor microenvironment (TME) and cellular interactions, far surpassing traditional two-dimensional (2D) cell culture systems. This review underscores the innovative advances in bladder cancer organoid technology, emphasizing their unique strengths in capturing intratumoral heterogeneity, enhancing drug sensitivity assessments, and facilitating personalized treatment approaches. We discuss diverse organoid systems, including spheroids, assembloids, and patient-derived organoid xenografts (PDOX), highlighting their exceptional ability to replicate individual patient tumor profiles. Furthermore, we explore integrated organoid-on-chip cultivation techniques incorporating 3D bioprinting and microfluidics, which notably improve precision, reproducibility, and scalability in organoid-based drug screening platforms. We advocate for optimized organoid cultivation protocols and synergistic integration with high-throughput analytical technologies, aiming ultimately to accelerate regimen breakthroughs in personalized medicine for bladder cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital& Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, China.
- Department of Urology, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaon…
- School of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian 116024, China. Electronic address: gedan@dlut.edu.cn.
Förderung
- National Natural Science Foundation of China
- Key Research and Development Program of Liaoning Province
- Natural Science Foundation of Liaoning Province
Zitieren
APA
Kang, H., Liu, X., Ge, D., & Zeng, Y. (2025). Revolutionizing bladder cancer research: Harnessing 3D organoid technology to decode tumor heterogeneity and propel personalized therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189454
Vancouver
Kang H, Liu X, Ge D, Zeng Y. Revolutionizing bladder cancer research: Harnessing 3D organoid technology to decode tumor heterogeneity and propel personalized therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189454
BibTeX
@article{Kang2025,
author = {Kang, Helin and Liu, Xi and Ge, Dan and Zeng, Yu},
title = {Revolutionizing bladder cancer research: Harnessing 3D organoid technology to decode tumor heterogeneity and propel personalized therapeutics},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
doi = {10.1016/j.bbcan.2025.189454}
}
EUVIMED